| Literature DB >> 32897884 |
Justin Taylor1,2, Mark Ta Donoghue3, Caleb Ho4, Kseniya Petrova-Drus4, Hikmat A Al-Ahmadie4, Samuel A Funt5, Yanming Zhang4, Umut Aypar4, Pavitra Rao3, Shweta S Chavan3, Michael Haddadin1, Roni Tamari6, Sergio Giralt6, Martin S Tallman7, Raajit K Rampal7, Priscilla Baez1, Rajya Kappagantula1, Satyajit Kosuri6, Ahmet Dogan4, Satish K Tickoo4, Victor E Reuter4, George J Bosl5, Christine A Iacobuzio-Donahue1,4, David B Solit1,3,5, Barry S Taylor1,3,8, Darren R Feldman5, Omar Abdel-Wahab1,7.
Abstract
Germ cell tumors (GCTs) are the most common cancer in men between the ages of 15 and 40. Although most patients are cured, those with disease arising in the mediastinum have distinctly poor outcomes. One in every 17 patients with primary mediastinal nonseminomatous GCTs develop an incurable hematologic malignancy and prior data intriguingly suggest a clonal relationship exists between hematologic malignancies and GCTs in these cases. To date, however, the precise clonal relationship between GCTs and the diverse additional somatic malignancies arising in such individuals have not been determined. Here, we traced the clonal evolution and characterized the genetic features of each neoplasm from a cohort of 15 patients with GCTs and associated hematologic malignancies. We discovered that GCTs and hematologic malignancies developing in such individuals evolved from a common shared precursor, nearly all of which harbored allelically imbalanced p53 and/or RAS pathway mutations. Hematologic malignancies arising in this setting genetically resembled mediastinal GCTs rather than de novo myeloid neoplasms. Our findings argue that this scenario represents a unique clinical syndrome, distinct from de novo GCTs or hematologic malignancies, initiated by an ancestral precursor that gives rise to the parallel evolution of GCTs and blood cancers in these patients.Entities:
Keywords: Cancer; Genetics; Hematology; Leukemias
Year: 2020 PMID: 32897884 PMCID: PMC7685753 DOI: 10.1172/JCI139682
Source DB: PubMed Journal: J Clin Invest ISSN: 0021-9738 Impact factor: 14.808